Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
FY2025 revenue $2.58bn (+0.7%); operating margin 1.8%; net income $759.9m.
Net income lifted by non-operating investment gains; operating profit was $47m.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Jul 2026: Bio-Rad began a global restructuring involving job cuts, consolidation of functions and facility closures, with estimated pre-tax charges of $80–90m, to be substantially complete by end of 2027, according to its SEC filing.
Data breaches, cyber incidents, regulator action and assurance status.
No confirmed data breaches, cyber incidents or regulator action involving Bio-Rad Laboratories found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
No product recalls, FDA warning letters or safety notices involving Bio-Rad Laboratories found in HSH's search of the last 24 months.
Contract delivery, go-lives, terminations and disputes.
No customer contract disputes, terminations or troubled implementations involving Bio-Rad Laboratories found in HSH's search of the last 24 months.